Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
|Articles|June 11, 2015
- Precision Medicine
- Volume 2
- Issue 1
Clinical Validation and Utility of a Liquid Biopsy in NSCLC
Author(s)Veena Singh, MD
Veena Singh, MD, senior vice president and senior medical director, Biocept, Inc., discusses the clinical validation and utility of a liquid biopsy in non-small cell lung cancer (NSCLC) using circulating tumor cells (CTCs) and ctDNA to analyze EGFR, ALK and ROS status.
Advertisement
Veena Singh, MD, senior vice president and senior medical director, Biocept, Inc., discusses the clinical validation and utility of a liquid biopsy in non-small cell lung cancer (NSCLC) using circulating tumor cells (CTCs) and ctDNA to analyze EGFR, ALK and ROS status.
<<<
Articles in this issue
over 11 years ago
Nivolumab and Future Biomarkers in NSCLCAdvertisement
Related to this article
SABR had higher 3-year all-cause mortality than surgery in early-stage NSCLC (30.3% vs 21.6%) in an emulated target trial; the gap narrowed at age 80 and older.
Hoth Therapeutics stopped the phase 2a CLEER-001 trial of topical HT-001 early after an interim review and will seek FDA input on phase 3.
Real-world study shows outpatient tarlatamab for relapsed SCLC is feasible, with mostly low-grade CRS, rare ICANS, low ICU use, and similar disease control.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
4
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
5